Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
20,586
Total Claims
$19.9M
Drug Cost
2,309
Beneficiaries
$8,605
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 5,101 Rheumatology providers
-51%
Opioid rate vs peers
2.0% vs 4.1% avg
+42%
Cost per patient vs peers
$8,605 vs $6,039 avg
+176%
Brand preference vs peers
21.0% vs 7.6% avg
Opioid Prescribing
2.0%
Opioid Rate
410
Opioid Claims
$4,176
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 4,303 claims · $18.5M
Generic: 16,235 claims · $1.4M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Pegloticase | 42 | $2.4M |
| Adalimumab | 236 | $1.7M |
| Abatacept/Maltose | 335 | $1.3M |
| Infliximab | 223 | $1.2M |
| Immun Glob G(Igg)/Gly/Iga Ov50 | 82 | $1.1M |
| Etanercept | 124 | $989K |
| Diclofenac Sodium | 2,308 | $926K |
| Upadacitinib | 134 | $897K |
| Golimumab | 119 | $852K |
| Belimumab | 232 | $681K |
| Denosumab | 380 | $629K |
| Tocilizumab | 210 | $615K |
| Abatacept | 101 | $586K |
| Rituximab | 23 | $438K |
| Teriparatide | 100 | $432K |
Prescribing Profile
Patient Profile
71
Avg Age
81%
Female
1.55
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About